Thermo Fisher to Buy Patheon NV
hermo Fisher Scientific has announced its intention to buy Patheon NV.
Thermo Fisher Scientific (Waltham, Massachusetts, USA) has announced its intention to buy Patheon NV (Amsterdam, The Netherlands), a manufacturer of drugs for clinical trials, for $5.2 billion as the company seeks to expand its products and services for the biopharma industry.
Thermo Fisher Chief Executive Marc Casper described the deal as a “hand in glove fit to… our fastest growing part of the business.”
The deal is expected to be completed by the end of the year, and Casper believes the purchase will allow for greater growth potential in the long run with “very interesting opportunities to build out their footprint in AsiaâPacific.” An area Thermo Fisher feels it has yet to penetrate.
“It’s really about expanding our capabilities,” said Casper. “We want to be able to offer our customers a menu of services.”
The buyout of Patheon is expected to more than double Thermo Fisher’s sales in the biopharma market.
For more information please visit, www.thermofisher.com
Simultaneous Screening of Pesticide Residues in Date Fruits with UHPLC–MS/MS and GC–MS/MS
March 7th 2025Comprehensive information was derived through the utilization of a QuEChERS-UHPLC–MS/MS and GC–MS/MS method for the detection of 211 volatile and stable pesticide residues in 90 date fruit samples.
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ions used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.
Pick Your Poison. Isolation of Paclitaxel (Mar 2025)
March 7th 2025The diterpenoid, paclitaxel, which was identified as a potent chemotherapy agent for breast and ovarian cancer originates from the Pacific Yew tree. The isolation of paclitaxel from its major impurities is shown with the use of Hamilton’s PRP-1 (5 µm) HPLC column.
